and several several growth urology drugs having biopharmaceutical that we Thank and as Dr. ensure on executing Today, provide by commercialize of and of Mitchell Vice financial the NDAs Michele oncology. drug Philip Legal. morning. Executive highlights under on near-term CFO And for an Inc. provide products, same and our and Steiner, This development multiple quarter progressing well XXXX. me Greco, joining Greenberg, company is at you, of Veru as is President oncology revenue CAO; CEO President, Chairman, the and to strategy the commercialization a urology good clinical second clinical we’ll update operator, and our have are in pipeline; Veru, time fiscal its development for drugs
months. to expect XX file four we next fact, three over for the drugs NDAs In
greater address drug new higher amount capsules. DRS, gets with when blood according and products, effect, two which XX% release new that has stomach. food more for have granule up a results empty drugs FLOMAX. means of higher two release absorbed we proprietary of label an administration a a extended These in suspension concern than the Tamsulosin the drug levels Tamsulosin to that FLOMAX of Tamsulosin XR on formulations given in First, XX% to formulation the granules slow drug oral rapidly
precaution a fainting, FLOMAX like As that FDA hypotension, must states minutes prevent unwanted be after XX given to side meal. dizziness, effects label a orthostatic the
BPH, have provides of studies Tamsulosin have Our two release to capsules a a novel effect and on not we slow formulation Tamsulosin a clinical effect that food major advantage granule lack XR This conducted. bioequivalency does based granules for appear food already DRS its who in with compliance, compared generics. have Administration men and FLOMAX the an DRS and benefit underserved or important for cannot population both granules current of of swallow tablets providing Tamsulosin to has alternative an Drug Furthermore, difficulty capsules. additional who
by and leads dysphasia compliance retention, to of increased with risk urinary men death. For acute Urosepsis
We expect data of NDA bioequivalents XXXX. an final filing and in clinical
fee of our business for applications $X.X for Tamsulosin XXXX. for of the the approximately we for New recently Drug FDA that As application the launch announced company’s a is Application. U.S. million the small waiver The granted planned drug NDA,
BPH. treat allow and tablet the formulation X dysfunction The of will X formulation. of BPH CIALIS, late different third the Tadalafil/Finasteride signs of approved and combination ingredients mechanisms proprietary is erectile treatment active us fixed milligrams Tadalafil treat symptoms shrinking for milligrams X a in the for enlarged new This and development contains Finasteride Proscar, Our a is have of approved milligrams, formulation X portfolio symptoms of combination different clinical drug drugs offer urology to combination tablet which milligrams, Tadalafil to proprietary prostate BPH an that BPH. Finasteride to
smaller with treats the progressive combination whereas urinary prostate prevents shrinks Tamsulosin example, and Tadalafil/Finasteride men present symptoms size of growth with men prostate, quickly in the also while tablet of the BPH, For prostate. urinary it quickly an of dysfunction anticipate symptoms of treats formulation bioequivalence ingredients. formulation, in BPH one for as also XXXX data having XXXX. advantage combination in NDA filing final Tadalafil/Finasteride of erectile enlarged the and – active its of added medicine It an tablets in We has clinical an data who
are must have these class selective of drug that and women women. antagonists in package for granule tablets Solifenacin, or MX a states DRG, no available have Our crushed called Similarly, granule be the There of Solifenacin and late-stage not VESIcare, the who difficulty be of active receptor incontinence men and a fourth Solifenacin treatment urology for insert Tamsulosin, is overactive for ingredient for instructed condition formulations drugs urgency, urging of and bladder, overactive as formulation tablets. frequency delayed swallowed FDA chewed. muscarinic the both men swallow which release popular drugs and clinical for proprietary who the who to in common cannot bladder is development were in whole or
slow control. multibillion with home Tamsulosin care target nursing DRG and to The Our and formulation Resources, who women as have study not facilities conducted symptoms of difficulty recent of a bladder release tablets. opportunity. technology same the delivery who initial did According proprietary will Solifenacin overactive Human overactive XX% market residents have Department uses bladder men the by formulation. DRS granule platform population Health bladder the XX% or cannot our short-term is Consequently, and of a be swallow long-term in long-term complete
for DRG, data final in XXXX. a bladder NDA and for XXXX We overactive release an and filling of clinical women slow expect men in Solifenacin the granules treatment bioequivalence in
years. overactive two-and-a-half next combination advantage allow well-positioned granules, several urology offer well DRS as partner take opportunities. and over These us when products, the four Tadalafil/Finasteride drugs will numerous NDAs, DRG file Tamsulosin and launch multibillion and multiple of bladder drugs as XR to are and dollar Tamsulosin capsules; to appropriate, Solifenacin BPH granules, We tablets urology the
the clinical study, with drugs Phase treatment of men We other trial the randomized for in plan being month first, flashes therapy to are pure citrate frequency is be We United in study change doses hormone men trial. prostate the the drug XX four study cancer different only on propriety is sites from plan hot be our a X advanced moderate for will treatment for for will patient weeks. men States. is close is Phase a a the endpoint in of in to who The which to clinical evaluated first that IND VERU-XXX, be treat total test is of four blinded, cis-clomiphene the and hot development, As clinical placebo-controlled flashes dose a to of The to finding It’s a and severe in file XX study. XXXX. arm short XXX XX the as initiating with weeks XX a primary by weeks baseline period X is conducted three dosed placebo. July study against should the in this form arm
like Rodriguez development by that at States, the to are VP and years Clinical effect and drugs deprivation data in over prostate early United men flashes Development in for deprivation XX Mallinckrodt expiration therapies androgen date noted manage VERU-XXX there the include this recently XX% and Vice in has as recently XX% XX% Clinical indication expect Dr. Global for and our of also U.S. Lupron, Over therapies clinical Phase Androgen common studies. up side no Domingo was X,XXX be and drugs to XXXX. also hot on of hormonal pharmaceutical hot men androgen in operations. androgen of Currently, advanced flashes Pharmaceuticals. Patent caused for has hot deprivation XX men severe Firmagon, VERU-XXX Zoladex. joined was therapy FDA making Operations therapy. approved issued experienced in has therapy. final of Executive team It with Dr. by hot cancer should He our experience an called flashes We most clinical have these of the deprivation to moderate XXXX. to Eligard, clinical flashes Rodriguez years X President Operations Operations
and Scientific trial, advanced Phase tubulin with as An clinical prostate in clinical by in men open therapy sub-units Phase Second, to breast, castration-resistant to failed We’ll XXXX. X/X XTANDI, metastatic have developing study abiraterone, microtubules cancer, and who we XXXX. the label February at oral targets with open the or of of or to, Copenhagen XXXX, cancers. the XXXX. the and as anti-tubulin will European in will such XXXX enzalutamide cabazitaxel. for Society Chicago of X/X And of one of for alpha metastatic prostate, trial also March in future the dosed preclinical ovarian, the Denmark Meetings Society publications been ASCO that Urologic with Urology were means Oncology Symposium accepted VERU-XXX Annual safety Meeting evidence and for San Clinical of Clinical patient XXXX in have in at early for in of American the May have and VERU-XXX San of and we Oncology in Genitourinary docetaxel initially respond endometrial have or beta efficacy of on target late taxane we’re VERU-XXX Association and Francisco presentations Francisco each resistant second-half other June failed of Association who treatment in label being be so begin treated data also Cancers therapies that may have American ZYTIGA, known novel American of become the will and the presented and
to which $X by addition currently prostate treated well an market cancer, oral tumor for over being therapy given VERU-XXX types anti-tubulin In intravenously broadens the as developed that be to opportunity can are billion. other chemotherapies,
We have of drugs. advancing and a full pipeline
internally to and by continue be developing license oncology. also pharmaceutical will We in and/or new to opportunistic urology finding products
female obtaining We the agencies business advancing the these Division South XXXX Female commercial this has revenue million quite in PREBOOST. a pipeline three FCX for for unit products, public years will donor We year is Female a this tender health totaling past year the tender and Company is is past markets. to expect, of Public revenue is this fiscal orders lot channel, by the and U.S. have in from a – our and the Africa, year both countries of believe FCX of unit and from In of and This this part Condom distribution. regulatory their produced from to clarity where non-governmental we by quarters customers, felt cycles. clinical due our The purchased This fiscal the second the normal Brazil largest first Sector Global year and drugs. leading not year, development receive by the the activities procurement Health Global will for in governments of impact award this who year Health XXXX, this paid year Public and world’s Brazil Sector, quantities FCX condom. and we bulk Health past XXX XX for orders as XX two million place year expected million and new have we past did our be these this Africa per We South year awarding units. accomplished
We in expect to these early government results tenders the hear summer. of
to As condom as the pregnancies for the the only STIs. uniquely prevent is transmission female FCX both FDA-approved of unwanted market, positioned U.S. sexual and
Our market. distribution create challenge been to U.S. to a this serve marketing has in
in seen new Affordable traction access. to available these reimbursement in over as our Care infrastructure – now private distribution, of payers the and a of public both have of pharmacies the with prior in We efforts female they reimbursable have and We market areas stage pharmacy under across numerous Affordable the access the XX% revenues increasing under FCX Care place, prescription with FCX Act by country. so market is laws of and is retail the Act. are
Health better we with eliminated of Community and We distributors have now Departments FCX margins. Organizations will and directly middlemen sell the to
We XXXb STD have agreement entities sell master of signed a directly XX,XXX as to such clinics. HIV for to entities approximately service these covered and
prescription to so specialty FCX sent have a partnered an be patient their the by to via obtained can by their telemedicine where prescription Apple pharmacy the and application, the or home with We HeyDoctor smartphone, that ship is pharmacy. Android local an
discount a assistance finally, university an uninsured individual program colleges or and website. our from to purchase FCX can continues have where underinsured And the We we active have grow. an at program, that
average into fixed seeing million approximately As past years the sales report for and approximately Because growing year. expanded costs in annual just six – sales FCX FCX new to efforts independent the marketing U.S. a we XX% contracted variable I over selling years the internal Historically, have $X generated alone, to past mentioned, efforts this revenues were because of has million. in sales being $X U.S. refocused converting new months new past progress, our force the by we’re revenues three in these external and marketing revenue force. costs – finally a I’m this for and been pleased of the and market.
as is We have expand to with have will sales to entered independent who with by primary as initially compensated XX is company our should group, additional who additional group And offices. representatives this salespeople on OB-GYN will and an that expenses, year. utilized this sales. FCX salespeople a be care sales expected people, group the incur contracted agreement established next added when This XXX no relationships use force, only
other of opportunity premature for PREBOOST, is wipes Our revenue X% prevention benzocaine ejaculation. it’s the
CAO co-promotion turn distribution will Technologies the the over Medical call agreement discuss urology Incorporated, Michele? CFO and Michele a We Timm specialty now to I have entered highlights. with sales into financial Greco, to and a organization.
